Correction to: Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer

Olarn Roengvoraphoj¹ · Cherylina Wijaya² · Chukwuka Eze¹ · Minglun Li¹ · Maurice Dantes¹ · Julian Taugner¹ · Amanda Tufman^{3,4} · Rudolf Maria Huber^{3,4} · Claus Belka^{1,4} · Farkhad Manapov^{1,4}

Published online: 14 March 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Correction to:

Strahlenther Onkol 2017

<https://doi.org/10.1007/s00066-017-1229-3>

Unfortunately, the structure of Table 4 was incorrect.
The corrected version of Table 4 can be found below.
We apologize for any inconvenience caused.

The online version of the original article can be found under
<https://doi.org/10.1007/s00066-017-1229-3>.

✉ Olarn Roengvoraphoj
Olarn.Roengvoraphoj@med.uni-muenchen.de

¹ Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

² Department of Pulmonology, Asklepios Fachkliniken München-Gauting, Munich, Germany

³ Respiratory Medicine and Thoracic Oncology, Internal Medicine V, Ludwig-Maximilians-University of Munich and Thoracic Oncology Centre Munich, Munich, Germany

⁴ members of the German Centre for Lung Research (DZL CPC-M), Giessen, Germany

Table 4 A summary of clinical trials showing correlation between PET/CT and overall survival in patients with NSCLC

Study	Patient no.	NSCLC stage	Pre-treatment PET/CT	Mid-treatment PET/CT	Post-treatment PET/CT	Endpoint
Machtay et al. (2013) [9]	250	Inoperable stage IIB/III	SUV peak	Not performed	SUV peak	2-Year OS post-treatment SUVpeak > 5 38% vs. 53% Observation arm ($p = 0.001$)
Usmanij et al. (2013)[10]	28	Inoperable stage III	TLG	Not performed	TLG	Delta TLG decrease of 38% was associated with prolonged PFS
Van Elmpt et al. (2012) [11]	34	Stage II–IV	SUVmean, SUVmax	SUVmean, SUVmax	Not performed	For patients with a decrease in SUV >15%, 2-year OS was 92%, compared with a median OS of 19 months, and a 33% 2-year OS, respectively, for the patients with a decrease in mean SUV of less than 15%
Ohri et al. (2015) [24]	214	Inoperable stage IIB/III	MTV	Not performed	Not performed	Median OS for patients with MV < 95.4 cm ³ 23.6 vs. 13.4 months ($p < 0.001$)
Markovina et al. (2015) [27]	176	Inoperable stage IIB/III	Not performed	Not performed	SUV of RLNs	Not associated with OS
Ohri et al. (2016) [25]	201	Inoperable stage IIB/III	MTV, SUVmax	Not performed	Not performed	Median OS for patients with pretreatment-MV < 93.3 cm ³ 22.6 vs. 20 months ($p < 0.001$)
Bazan et al. (2017) [13]	230	Inoperable stage IIB/III	MTV	Not performed	Not performed	Median OS for patients with pretreatment MTV > 32 cm ³ 14.8 vs. 29.7 months ($p < 0.001$)
Ohri et al. (2017) [26]	89	Inoperable stage III	MTV	Not performed	MTV	A 30-month cumulative incidence rate of 23% for lesions above 25 cm ³ compared with 4% for lesions below 25 cm ³ ($p = 0.008$)
Current study	65	Inoperable stage III	PT-MV	PT-MV	PT-MV	Median OS for patients with pre-treatment PT-MV < 63 cm ³ 26 vs. 11 months ($p < 0.001$), median OS for patients with post-treatment PTV-MV < 25 cm ³ 23 vs. 9 months ($p < 0.001$)

CT computed tomography, *PET* positron emission tomography, *SUV* standardized uptake value, *TLG* total lesion glycolysis, *MV* metabolic volume, *MTV* metabolic tumor volume, *RLNs* regional lymph nodes